{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:24:09Z","timestamp":1781346249689,"version":"3.54.1"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T00:00:00Z","timestamp":1065052800000},"content-version":"vor","delay-in-days":2253,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1997,8]]},"abstract":"<jats:p><jats:italic>Aims<\/jats:italic>\u2007To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1.5\u2003g every 12\u2003h) and in whom impaired renal function was diagnosed.<\/jats:p><jats:p><jats:italic>Methods\u2007The patient received vigabatrin (0.5\u2003g\u2003day<jats:sup>\u22121<\/jats:sup><\/jats:italic>\u200a). A pharmacokinetic study of the S(+) and R(\u2212) enantiomers of vigabatrin was performed before and during dialysis. Plasma concentrations were measured at 0, 1, 2, 3, 4, 6, 12, 18 and 24\u2003h by a specific GCMS assay.<\/jats:p><jats:p><jats:italic>Results\u2007Before dialysis, the maximum and minimun plasma concentrations of vigabatrin at steady\u2010state were lower for the S(+) than for the R(\u2212) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(\u2212) enantiomer (2.97 vs 0.48 l\u2003h<jats:sup>\u22121<\/jats:sup>\u200a). In addition, the haemodialysis clearance was similar for the two enantiomers (4.96 vs 5.15 l\u2003h<jats:sup>\u22121<\/jats:sup><\/jats:italic>\u200a).<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>\u2007Vigabatrin is an irreversible inhibitor of GABA\u2010transaminase, effective in the treatment of drug\u2010resistant epilepsy and reported to be eliminated unchanged by renal excretion. Although vigabatrin is known to have stereoselective kinetics, the difference in plasma dry concentrations and pharmacokinetics of the S(+) and R(\u2212) enantiomers that we observed during long term administration at high doses in a patient with impaired renal function, has not been reported before. The question remains of the potential toxicity of the high levels of the R(\u2212) enantiomer.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1997.00636.x","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T19:13:18Z","timestamp":1066158798000},"page":"183-185","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics of the S(+) and R(\u2212) enantiomers of vigabatrin during chronic dosing in a patient with renal failure"],"prefix":"10.1111","volume":"44","author":[{"given":"Evelyne","family":"Jacqz\u2010Aigrain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Guillonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Alice","family":"Macher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,2]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00636.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00636.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00636.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00636.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:10:17Z","timestamp":1694405417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1997.00636.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["10.1046\/j.1365-2125.1997.00636.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00636.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8]]}}}